Accustem Sciences Inc. (ACUT) 是一家上市公司 属于 医疗保健 板块，经营于 生物科技 行业. 公司总部位于 New York City, NY, 美国. 现任CEO为 Wendy E. Blosser.
ACUT 拥有 IPO日期为 2022-03-03, 2 名全职员工, 在 Other OTC, 市值为 $5.79M.
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
